2015年3月21日 讯/生物谷BIOON/--阿斯利康于本周四宣布，与第一三共制药达成协议，将在美国共同推销其治疗便秘的药物MOVANTIC。
MOVANTIC是一线mu受体靶向药物，用于治疗非癌症诱发的阿片类药物引起的便秘（OIC）。OIC在数百万服用阿片类药物阵痛的患者中是一种最常见的副作用之一。阿斯利康于2009年从Nektar公司获得了Movantic的专有权。
2014年9月该药物作为可每日一次的口服药获得美国FDA批准上市。2015年1月毒品管理局在受控物质附表二中删除了该药物。因此，该药物的市场松绑预计在今年4月初。
根据合作条款，日本企业第一三共制药将预付2亿美元，后续的销售支出将达到6.25亿美元。阿斯利康将负责该药物的生产和销售，这两家公司将共同进行市场推广。阿斯利康还将支付第一三共的销售佣金。
两公司之间的市场合作协议赞许了两家公司的增长战略。阿斯利康的价值目标是通过自身努力和外部支持的商业活动共同拓展其药物组合，而这次交易的顺利顺利进展与阿斯利康的价值观相符。阿斯利康董事长Paul Hudson表示，该协议反映了他们通过外源活动创造价值的商业模式。
这笔交易也同样符合第一三共的战略模式，他们试图在美国通过自身的研发和与外部合作伙伴的联盟扩大其药物组合。第一三共董事长Ken Keller表示，Movantic不仅有助于治疗由于抑制疼痛而引起的常见副作用，而且为第一三共提供了一个机会继续构建其在这一治疗领域的药物组合。
生物谷推荐英文原文报道：
AstraZeneca plc (ADR) And Daiicho Sankyo To Co-Market OIC Drug Movantik In The US
AstraZeneca plc (ADR) (NYSE:AZN) announced on Thursday an agreement with Daiichi Sankyo Co LT (OTCMKTS:DSKYF) to jointly market its constipation drug MOVANTIK in the US.
MOVANTIK is a first-in-class mu receptor-targeting drug designed to treat opioid-induced constipation (OIC) that is not triggered by cancer. OIC is one of the most common side effects of prescription opioid pain medication taken by millions of people each year. AstraZeneca gained exclusive rights over Movantik in 2009 as part of a licensing agreement with Nektar Therapeutics (NASDAQ:NKTR). The once-daily oral drug was approved by the US Food and Drug Administration in September 2014. The drug's "schedule II controlled substance" designation was removed by the Drug Enforcement Administration (DEA) in January 2015. Its market release is scheduled to occur by early April in the US.
As per the contract terms, Japan-based Daiichi Sankyo will make an upfront payment of $200 million to be subsequently followed by various sales-related outlays reaching $625 million. AstraZeneca is going to be in charge of the manufacturing and sales of the drug, while both companies will market it together. AstraZeneca will also be responsible to pay commissions resulting from the sales to Daiicho Sankyo Inc.
The co-marketing agreement between Daiichi and AstraZeneca compliments both the companies' respective growth strategies. The deal goes well with AstraZeneca's goal of delivering value from its drug portfolio by expanding on its commercialization activities in US through its own efforts as well as relevant external help.
Paul Hudson, the President of AstraZeneca US said regarding the deal, "Our agreement reflects our evolving business model by creating value from our portfolio through externalisation activity." The deal is also in line with Daiichi Sankyo's strategy of expanding its drug portfolio in US through its own R&D efforts as well as acquisitions and strategic alliances with external partners. According to Ken Keller, the President of Daiichi Sankyo , US Commercial, Movantik not only helps in combating "one of the most common conditions arising from widely used pain medications" but also provides " an opportunity to continue to build the Daiichi Sankyo US portfolio of medicines in this therapeutic area."
Movantic was a third of its kind OIC treatment approved by FDA in 2014. Amitiza of Sucampo Pharmaceuticals, Inc (NASDAQ:SCMP) was approved in April soon to be followed by Relistor of Salix Pharmaceuticals Ltd (NASDAQ:SLXP) in July.